Hard stools are more difficult and painful to pass than soft stools
Food and Drug Administration (FDA) approved the first oral formulation of semaglutide specifically for chronic weight management in adults
Dec 29, 2025 Cagrilintide is a long-acting amylin receptor agonist that produces 10-12% body weight loss through mechanisms completely different from GLP-1s - dramatically slowing gastric emptying, suppressing appetite via brain amylin receptors, and reducing postprandial glucose
The compounded semaglutide dose chart provides specific measurement guidance for various compounded concentrations
Your body can only utilize so much protein for muscle protein synthesis at one time, roughly 30 to 40 grams depending on age and activity level
These drugs are FDA-approved for type 2 diabetes and obesity, but growing evidence supports their use for rheumatoid arthritis, psoriatic arthritis, lupus, osteoarthritis, and metabolic/autoimmune diseases. Who should not take GLP-1 medications
.png)
